Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients
- 18 May 2019
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 71 (10) , 1670-1680
Abstract
Objective: The efficacy of rituximab (RTX) in systemic lupus erythematosus (SLE) is a subject of debate. This study was undertaken to investigate the outcomes of RTX treatment in a European SLE cohort, with an emphasis on the role of RTX as a maintenance agent.Methods: All patients with SLE who were receiving RTX as induction therapy in 4 centers were included. Patients who received a single course of RTX and those who received RTX maintenance treatment (RMT) were followed up after treatment. Disease flares during the follow‐up period were defined as an increase in disease activity and the number or dose of immunosuppressive drugs.Results: Of 147 patients, 27% experienced treatment failure at 6 months. In a multivariate analysis, a low number of previous immunosuppressive therapies (P = 0.034) and low C4 levels (P = 0.008) reduced the risk of treatment failure. Eighty patients received RMT over a median of 24.5 months during which 85 relapses, mainly musculoskeletal, were recorded (1.06 per patient). At the time of the last RTX course, 84% of the patients were in remission. Twenty‐eight (35%) of 80 patients never experienced a flare during RMT and had low damage accrual. Active articular disease at the time of the first RTX administration was associated with a risk of flare during RMT (P = 0.011). After RMT, relapse‐free survival was similar to that in patients receiving a single RTX course (P = 0.72).Conclusion: RMT is a potential treatment option for patients with difficult‐to‐treat disease. Relapses occur during RMT and are more likely in those with active articular disease at the time of the first RTX administration. Relapse risk after RMT remains high and apparently comparable to that seen after a single RTX course.Keywords
This publication has 35 references indexed in Scilit:
- Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic reviewSeminars in Arthritis and Rheumatism, 2017
- The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adultsRheumatology, 2017
- Lupus nephritis and B-cell targeting therapyExpert Review of Clinical Immunology, 2017
- Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial DesignArthritis & Rheumatology, 2017
- New insights into the immunopathogenesis of systemic lupus erythematosusNature Reviews Rheumatology, 2016
- Rituximab versus Azathioprine for Maintenance in ANCA-Associated VasculitisNew England Journal of Medicine, 2014
- An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus CohortRheumatology, 2014
- Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB studyLupus, 2012
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab studyArthritis & Rheumatism, 2012
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009